Clinical Trial Update: AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update on anti-CD19 CAR-T cells for relapsed or refractory non-Hodgkin lymphoma, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD19 CAR T cells (CD19-directed CAR T cells)

Snippet

Sponsor: Benjamin Tomlinson | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING